Breast milk provides real, measurable protection against viruses through multiple overlapping defense systems. It contains antibodies that neutralize pathogens, sugar molecules that trick viruses into binding to the wrong target, proteins that block viral entry into cells, and even living immune cells from the mother. These aren’t trace amounts of vaguely helpful compounds. Colostrum, the thick first milk produced after birth, contains roughly 5.9 mg/mL of the primary protective antibody, IgA, and even mature milk maintains concentrations around 3.7 mg/mL weeks later.
How Antibodies in Milk Neutralize Viruses
The most well-studied antiviral component in breast milk is secretory IgA, or sIgA. This antibody works by coating the mucosal surfaces of your baby’s gut, throat, and respiratory tract, creating a barrier that prevents viruses from latching onto cells and starting an infection. Unlike antibodies that circulate in the blood, sIgA is specifically designed to survive the harsh environment of the digestive system and function on wet tissue surfaces.
What makes this system remarkably targeted is that a mother’s body generates sIgA antibodies against the specific pathogens she encounters. When a mother is exposed to a virus, immune cells in her gut and airways identify it, then migrate to breast tissue where they produce antibodies tailored to that exact threat. Those antibodies pass directly into her milk. This means breast milk is not a static product; it’s a living, responsive immune supplement that adapts to the mother’s environment, which is almost always the same environment the infant shares.
Research on COVID-19 provided a clear example. After maternal mRNA vaccination, both IgG and IgA antibodies against the SARS-CoV-2 spike protein increased in breast milk, peaking one to four weeks after the vaccine series was completed. Binding antibodies against multiple variants (Alpha, Beta, Delta, Gamma) were detected in milk collected shortly after vaccination. The neutralizing response in breast milk was more modest than in blood, roughly a twofold increase, but it was measurable and present. One limitation: the vaccine did not produce neutralizing antibodies against the Omicron BA.4/5 variant in either blood or breast milk, suggesting that variant-specific boosters may be needed for optimal protection against newer strains.
Sugar Molecules That Act as Viral Decoys
Breast milk contains over 200 types of complex sugars called human milk oligosaccharides, or HMOs, that the infant cannot digest. These sugars aren’t there for nutrition. They serve as decoy receptors that intercept viruses before they can reach intestinal cells.
The mechanism is elegant. Many viruses begin infection by recognizing and binding to specific sugar structures on the surface of cells lining the gut. HMOs share structural similarities with those cell-surface sugars, so viruses latch onto the free-floating HMOs instead. Once a virus binds to an HMO, it’s effectively neutralized, unable to attach to actual cells. HMOs also work in a second way: they can bind directly to cell-surface receptors, physically blocking the docking sites viruses need.
Rotavirus, one of the most common causes of severe diarrhea in infants, is particularly susceptible to this strategy. Both fucosylated and sialylated HMOs reduce rotavirus infection by mimicking the blood group antigens the virus normally targets. X-ray crystallography has shown that specific HMOs fit into a binding pocket on the rotavirus surface protein, acting as structural mimics that prevent the virus from recognizing real cell receptors. Similar decoy activity has been observed against norovirus and other enteric pathogens.
Lactoferrin Blocks Viral Entry
Lactoferrin is an iron-binding protein found in high concentrations in breast milk, and it has broad antiviral activity against a range of enveloped viruses, including influenza, hepatitis B and C, Zika, dengue, and SARS-CoV-2. Its primary mechanism involves physically occupying the docking sites that viruses use to enter cells.
Many viruses initiate infection by attaching to molecules called heparan sulfate proteoglycans on cell surfaces. Lactoferrin accumulates near these same molecules, effectively blocking the landing pads viruses need. Against dengue, for instance, lactoferrin is most effective when it arrives before the virus does, because it prevents the initial attachment step. Against SARS-CoV-2, lactoferrin has been shown to interfere with the spike protein’s ability to bind the ACE2 receptor, the primary entry point the virus uses. Against influenza, it works differently: lactoferrin carries sugar molecules on its surface that act as competitive substrates, diverting the virus away from host cells, and it can also bind directly to viral particles to disrupt the uncoating stage of infection.
This breadth of activity is notable. Lactoferrin doesn’t just target one virus. It disrupts a common entry strategy shared by many viral families, making it one of the more versatile antiviral components in breast milk.
Living Immune Cells From the Mother
Breast milk contains maternal white blood cells that provide active immunity to the infant. These cells are not passive passengers. They perform phagocytosis (engulfing pathogens), secrete antimicrobial compounds including cytokines and immunoglobulins, and present antigens to help train the infant’s developing immune system.
Perhaps most striking, these maternal immune cells don’t just work inside the infant’s gut. Research indicates they can cross the intestinal barrier and enter the infant’s systemic circulation, reaching distant tissues. The concentration of these cells is not fixed: when either the mother or the infant develops an infection, the number of leukocytes in breast milk rises rapidly, suggesting the mammary gland actively ramps up immune cell production in response to threats.
Colostrum Delivers the Highest Dose
The first milk produced after birth, colostrum, is particularly concentrated in immune factors. IgA levels in colostrum average 5.92 mg/mL, compared to 3.72 mg/mL in mature milk. IgM shows an even steeper decline, dropping from 0.44 mg/mL in colostrum to 0.09 mg/mL in mature milk. IgG, by contrast, remains relatively stable, hovering around 0.10 to 0.11 mg/mL throughout lactation.
This front-loading of immune protection makes biological sense. Newborns have virtually no immune defenses of their own in the first days of life. Colostrum delivers a concentrated dose of antibodies during the window of highest vulnerability. Even small volumes of colostrum, which is produced in teaspoons rather than ounces, carry enough immunoglobulin to begin coating the infant’s mucosal surfaces.
Measurable Protection Against Illness
The combined effect of these components translates into real clinical outcomes. Exclusive breastfeeding for more than four months is associated with a 72% reduction in the risk of hospitalization for lower respiratory tract infections during the first year of life. RSV, the leading cause of bronchiolitis in infants, is one of the primary drivers of those hospitalizations.
Breastfeeding also appears to enhance how well infants respond to their own vaccinations. In a study comparing breastfed and formula-fed infants who received the same conjugate vaccine at 2, 4, and 6 months of age, antibody levels were significantly higher in the breastfed group at 7 months (29.8 vs. 17.5 μg/mL) and at 12 months (4.8 vs. 3.0 μg/mL). The effect wasn’t apparent at the earliest time points, suggesting breast milk supports the maturation of the infant’s immune response over time rather than simply providing a short-term antibody boost.
When Viruses Can Pass Through Milk
While breast milk is broadly protective, a small number of viruses can be transmitted through it. HIV is the most clinically significant. For mothers on antiretroviral therapy who maintain an undetectable viral load, the risk of transmitting HIV through breastfeeding is less than 1%, but it is not zero. In settings where safe formula preparation is feasible, formula feeding or pasteurized donor milk eliminates this postnatal transmission risk entirely. In settings where clean water and formula are unavailable, the survival benefits of breastfeeding generally outweigh the small transmission risk for mothers on effective treatment.
Donor Milk Loses Some Antiviral Strength
Pasteurized donor milk from a milk bank undergoes Holder pasteurization, which heats milk to 62.5°C for 30 minutes. This process eliminates infectious pathogens but comes at a cost to some immune components. sIgA and lactoferrin levels drop significantly after pasteurization. HMOs, on the other hand, are heat-stable and survive the process largely intact. This means donor milk retains its decoy-receptor activity against gut viruses like rotavirus but loses much of its antibody-based and lactoferrin-based antiviral protection. For premature or vulnerable infants who cannot receive their own mother’s milk, donor milk still offers meaningful benefits over formula, but it is immunologically weaker than fresh breast milk.